ALDX

Aldeyra Therapeutics Inc.

Last Updated:

Q3 '20

Price

quotes and stock data delayed 15 minutes

Cash

$71.2M

Burn Rate (Qtr)

$8.9M

Company Profile

Aldeyra Therapeutics is a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra’s lead investigational drug product candidates are potential first-in-class treatments in development for dry eye disease, allergic conjunctivitis, and proliferative vitreoretinopathy. The company is also developing other product candidates for retinal and systemic inflammatory diseases.

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information

Drug | Disease (links)

Stage (next event)

Catalyst Date

Reproxalap

Dry Eye Disease

Phase 3 To be Initiated

Q4 2020

ADX-2191 (DHFR inhibitor)

Proliferative Vitreoretinopathy

Phase 3 to be initiated

2021

Reproxalap (ADX-102)

Allergic Conjunctivitis

Phase 3 Readout

H1 2020

ADX-629

COVID-19

Phase 2 to be initiated

Q4 2020

Recent Posts

See what the community is saying - click to see full post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon